AKT1 and neoplasm: With recent technical advances for minimally invasive mutation detection in circulating tumor DNA (ctDNA), we subsequently also evaluated the OncoBEAMTM assay to enable plasma specimens as additional diagnostic opportunity for AKT1 E17K mutation testing.